LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BT-20 | SU11274 | 3.33 | uM | LJP5 | 2 | J08 | 72 | hr | 1657 | 4803 | 5505 | 0.8724 | 0.8174 |
BT-20 | SU11274 | 3.33 | uM | LJP5 | 3 | J08 | 72 | hr | 1657 | 4656 | 5505 | 0.8457 | 0.7792 |
BT-20 | Fedratinib | 3.33 | uM | LJP5 | 1 | L02 | 72 | hr | 1657 | 3765 | 5505 | 0.6838 | 0.5476 |
BT-20 | Fedratinib | 3.33 | uM | LJP5 | 2 | L02 | 72 | hr | 1657 | 3942 | 5505 | 0.7160 | 0.5936 |
BT-20 | Fedratinib | 3.33 | uM | LJP5 | 3 | L02 | 72 | hr | 1657 | 3902 | 5505 | 0.7087 | 0.5832 |
BT-20 | TGX221 | 3.33 | uM | LJP5 | 1 | H20 | 72 | hr | 1657 | 5513 | 5505 | 1.0013 | 1.0019 |
BT-20 | TGX221 | 3.33 | uM | LJP5 | 2 | H20 | 72 | hr | 1657 | 5721 | 5505 | 1.0391 | 1.0560 |
BT-20 | TGX221 | 3.33 | uM | LJP5 | 3 | H20 | 72 | hr | 1657 | 5434 | 5505 | 0.9870 | 0.9814 |
BT-20 | Torin1 | 3.33 | uM | LJP6 | 1 | O14 | 72 | hr | 1657 | 1051 | 5505 | 0.1909 | -0.1577 |
BT-20 | Torin1 | 3.33 | uM | LJP6 | 2 | O14 | 72 | hr | 1657 | 1169 | 5505 | 0.2123 | -0.1270 |
BT-20 | Torin1 | 3.33 | uM | LJP6 | 3 | O14 | 72 | hr | 1657 | 1500 | 5505 | 0.2725 | -0.0410 |
BT-20 | Torin2 | 3.33 | uM | LJP5 | 1 | I20 | 72 | hr | 1657 | 1078 | 5505 | 0.1958 | -0.1507 |
BT-20 | Torin2 | 3.33 | uM | LJP5 | 2 | I20 | 72 | hr | 1657 | 1111 | 5505 | 0.2018 | -0.1421 |
BT-20 | Torin2 | 3.33 | uM | LJP5 | 3 | I20 | 72 | hr | 1657 | 963 | 5505 | 0.1749 | -0.1806 |
BT-20 | Tozasertib | 3.33 | uM | LJP5 | 1 | B14 | 72 | hr | 1657 | 1638 | 5505 | 0.2975 | -0.0051 |
BT-20 | Tozasertib | 3.33 | uM | LJP5 | 2 | B14 | 72 | hr | 1657 | 1527 | 5505 | 0.2774 | -0.0340 |
BT-20 | Tozasertib | 3.33 | uM | LJP5 | 3 | B14 | 72 | hr | 1657 | 1716 | 5505 | 0.3117 | 0.0151 |
BT-20 | Trametinib | 3.33 | uM | LJP5 | 1 | P20 | 72 | hr | 1657 | 4075 | 5505 | 0.7402 | 0.6282 |
BT-20 | Trametinib | 3.33 | uM | LJP5 | 2 | P20 | 72 | hr | 1657 | 3989 | 5505 | 0.7245 | 0.6059 |
BT-20 | Trametinib | 3.33 | uM | LJP5 | 3 | P20 | 72 | hr | 1657 | 4398 | 5505 | 0.7988 | 0.7121 |
BT-20 | TWS119 | 3.33 | uM | LJP5 | 1 | M02 | 72 | hr | 1657 | 4727 | 5505 | 0.8586 | 0.7976 |
BT-20 | TWS119 | 3.33 | uM | LJP5 | 2 | M02 | 72 | hr | 1657 | 4049 | 5505 | 0.7354 | 0.6214 |
BT-20 | TWS119 | 3.33 | uM | LJP5 | 3 | M02 | 72 | hr | 1657 | 4625 | 5505 | 0.8400 | 0.7711 |
BT-20 | Vemurafenib | 3.33 | uM | LJP5 | 1 | C14 | 72 | hr | 1657 | 5379 | 5505 | 0.9770 | 0.9671 |
BT-20 | Vemurafenib | 3.33 | uM | LJP5 | 2 | C14 | 72 | hr | 1657 | 4873 | 5505 | 0.8851 | 0.8356 |